Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum Days for Combined Screening- Roche (Astraia) Test Report

The maximum days for obtaining the test report for Combined Screening- Roche (Astraia) is typically 7-10 business days. However, this timeframe may vary depending on the laboratory's workload and processing times. Patients are advised to consult with their healthcare provider or the testing facility for more specific information on when they can expect to receive their test results.

What are the prerequisites for the test Combined Screening- Roche (Astraia)

  • Maternal age must be between 18 to 50 years
  • Singleton or twin pregnancy
  • Gestational age between 9 weeks 0 days and 13 weeks 6 days
  • Confirmed viable pregnancy by ultrasound
  • No known fetal abnormalities
  • No history of previous trisomy 21, 18, or 13 pregnancies

What are the measure values for the test Combined Screening- Roche (Astraia)

  • NT: Measured in mm
  • PAPP-A: Measured in mIU/L
  • hCG: Measured in ng/mL
  • AFP: Measured in ng/mL
  • uE3: Measured in ng/mL

What does this test Combined Screening- Roche (Astraia) identify?

Combined Screening - Roche (Astraia)

The Combined Screening test by Roche (Astraia) is used to identify the risk of certain chromosomal abnormalities in a fetus during pregnancy. This test combines the results of a blood test measuring specific proteins and hormones in the mother's blood with an ultrasound examination of the fetus.

The test specifically looks for markers such as PAPP-A (pregnancy-associated plasma protein A) and free beta-hCG (human chorionic gonadotropin) in the mother's blood. An abnormal level of these markers could indicate a higher risk of conditions such as Down syndrome, trisomy 18, or trisomy 13 in the fetus.

The ultrasound examination assesses factors such as nuchal translucency (the thickness of the skin at the back of the fetus's neck) and the presence of a nasal bone. The combination of these results helps to provide a more accurate assessment of the fetus's risk for chromosomal abnormalities.

Why is this test Combined Screening- Roche (Astraia) taken?

  • Combined Screening- Roche (Astraia) Test

    The Combined Screening- Roche (Astraia) test is taken to assess the risk of certain chromosomal abnormalities in a developing fetus during pregnancy. This test combines the results of a blood test measuring certain proteins and hormones in the mother's blood along with an ultrasound examination to provide a more accurate evaluation of the risk for conditions such as Down syndrome, trisomy 18, and neural tube defects.

    By analyzing both the biochemical markers in the blood and the ultrasound findings, healthcare providers can offer pregnant women more personalized counseling and potentially recommend further diagnostic testing if necessary. This test is typically offered to pregnant women between 11 to 14 weeks of gestation.

No FAQs available.

Customer Google Rating